Results 31 to 40 of about 14,528 (265)
Clinical experience with the ATS 3f Enable® Sutureless Bioprosthesis [PDF]
, 2011 The ATS 3f Enable® Bioprosthesis is a self-expanding valve with a tubular design that allows for decreased leaflet stress and preservation of aortic sinuses. We report the midterm results of a prospective, multicenter clinical study evaluating the safety
Thierry Carrel +18 more
core +1 more source
Experience with the Mitroflow aortic bioprosthesis [PDF]
The Journal of Thoracic and Cardiovascular Surgery, 1994 From October 1985 to May 1990, the Mitroflow bovine pericardial valve was placed in the aortic position in 168 patients (97 men, 71 women) with a mean age of 69.7 years. Eighty-nine patients had isolated aortic valve replacement, and 79 had aortic valve replacement and additional procedures.
R A, Moggio +5 more
openaire +2 more sources
European Heart Journal, 2020 AIMS In the last decade, transcatheter aortic valve (TAV) replacement determined a paradigm shift in the treatment of patients with severe symptomatic aortic stenosis. Data on long-term TAV performance are still limited.
L. Testa +21 more
semanticscholar +1 more source
Pulsed Cavitational Ultrasound Softening
JACC: Basic to Translational Science, 2017 The authors propose a novel noninvasive therapeutic approach for degenerative calcified bioprosthetic heart valves based on pulsed cavitational ultrasound (PCU) to improve the valvular function by remotely softening calcified stiff cusps. This study aims
Olivier Villemain, MD +9 more
doaj +1 more source
Human aortic bioprosthesis [PDF]
European Journal of Cardio-thoracic Surgery, 2008 We have read with the greatest interest the paper by Wolfgang A. Goetz et al. entitled Truly stentless molded autologous pericardial aortic valve prosthesis with single point attached commissures in a sheep model [1]. We congratulate the authors on their achievements in the development of valve bioprosthesis.
Wilczyński, L., Zembala, M.
openaire +2 more sources
Intermediate-term outcomes of aortic valve replacement using a bioprosthesis with a novel tissue.
Journal of Thoracic and Cardiovascular Surgery, 2020 OBJECTIVES The COMMENCE trial was conducted to evaluate the safety and effectiveness of an aortic bioprosthesis with novel RESILIA tissue (Edwards Lifesciences, Irvine, Calif).
D. Johnston +4 more
semanticscholar +1 more source
Journal of Thoracic and Cardiovascular Surgery, 2020 BACKGROUND The implantation of rapid-deployment aortic valves may interfere with the conduction system of the heart. This study evaluates the occurrence and predictive factors of conduction anomalies in patients undergoing surgical aortic valve ...
Iuliana Coti +7 more
semanticscholar +1 more source
Aortic Valve Replacement with a Conventional Stented Bioprosthesis versus Sutureless Bioprosthesis: a Study of 763 Patients [PDF]
, 2018 Objective: The aim of this retrospective study was to compare early postoperative outcomes after aortic valve replacement (AVR) with sutureless bioprostheses and conventional stented bioprostheses implanted through median sternotomy.
Thasee Pillay +29 more
core +1 more source
Thrombocytopenia after implantation of the Perceval S aortic bioprosthesis.
Journal of Thoracic and Cardiovascular Surgery, 2020 OBJECTIVE The Perceval S bioprosthesis (LivaNova PLC, London, United Kingdom) is based on the Freedom Solo aortic bioprosthesis (LivaNova PLC), which has been reported to be associated with perioperative thrombocytopenia.
MD Philipp Stegmeier +5 more
semanticscholar +1 more source
Arquivos Brasileiros de Cardiologia, 2007 FUNDAMENTO: Identificação de fatores de risco pré-operatórios na cirurgia cardíaca valvar visa melhor resultado cirúrgico pela possível neutralização de condições relacionadas com morbi-mortalidade aumentada.
Mateus W. De Bacco +9 more
doaj +1 more source